Metabolic syndrome: A sympathetic disease?

Markus Schlaich, Nora Straznicky, Elisabeth Lambert, Gavin Lambert

Research output: Contribution to journalComment/debate

44 Citations (Scopus)

Abstract

Metabolic syndrome is associated with adverse health outcomes and is a growing problem worldwide. Although efforts to harmonise the definition of metabolic syndrome have helped to better understand the prevalence and the adverse outcomes associated with the disorder on a global scale, the mechanisms underpinning the metabolic changes that define it are incompletely understood. Accumulating evidence from laboratory and human studies suggests that activation of the sympathetic nervous system has an important role in metabolic syndrome. Indeed, treatment strategies commonly recommended for patients with metabolic syndrome, such as diet and exercise to induce weight loss, are associated with sympathetic inhibition. Pharmacological and device-based approaches to target activation of the sympathetic nervous system directly are available and have provided evidence to support the important part played by sympathetic regulation, particularly for blood pressure and glucose control. Preliminary evidence is encouraging, but whether therapeutically targeting sympathetic overactivity could help to prevent metabolic syndrome and attenuate its adverse outcomes remains to be determined.

Original languageEnglish
Pages (from-to)148-157
Number of pages10
JournalThe Lancet Diabetes and Endocrinology
Volume3
Issue number2
DOIs
Publication statusPublished - 1 Feb 2015
Externally publishedYes

Fingerprint

Sympathetic Nervous System
Blood Glucose
Weight Loss
Pharmacology
Exercise
Diet
Blood Pressure
Equipment and Supplies
Health
Therapeutics

Cite this

Schlaich, Markus ; Straznicky, Nora ; Lambert, Elisabeth ; Lambert, Gavin. / Metabolic syndrome : A sympathetic disease?. In: The Lancet Diabetes and Endocrinology. 2015 ; Vol. 3, No. 2. pp. 148-157.
@article{f998a8fcdd0f4d1099d3cf5d5a8fa07d,
title = "Metabolic syndrome: A sympathetic disease?",
abstract = "Metabolic syndrome is associated with adverse health outcomes and is a growing problem worldwide. Although efforts to harmonise the definition of metabolic syndrome have helped to better understand the prevalence and the adverse outcomes associated with the disorder on a global scale, the mechanisms underpinning the metabolic changes that define it are incompletely understood. Accumulating evidence from laboratory and human studies suggests that activation of the sympathetic nervous system has an important role in metabolic syndrome. Indeed, treatment strategies commonly recommended for patients with metabolic syndrome, such as diet and exercise to induce weight loss, are associated with sympathetic inhibition. Pharmacological and device-based approaches to target activation of the sympathetic nervous system directly are available and have provided evidence to support the important part played by sympathetic regulation, particularly for blood pressure and glucose control. Preliminary evidence is encouraging, but whether therapeutically targeting sympathetic overactivity could help to prevent metabolic syndrome and attenuate its adverse outcomes remains to be determined.",
author = "Markus Schlaich and Nora Straznicky and Elisabeth Lambert and Gavin Lambert",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/S2213-8587(14)70033-6",
language = "English",
volume = "3",
pages = "148--157",
journal = "The Lancet Diabetes and Endocrinology",
issn = "2213-8587",
publisher = "Academic Press",
number = "2",

}

Metabolic syndrome : A sympathetic disease? / Schlaich, Markus; Straznicky, Nora; Lambert, Elisabeth; Lambert, Gavin.

In: The Lancet Diabetes and Endocrinology, Vol. 3, No. 2, 01.02.2015, p. 148-157.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Metabolic syndrome

T2 - A sympathetic disease?

AU - Schlaich, Markus

AU - Straznicky, Nora

AU - Lambert, Elisabeth

AU - Lambert, Gavin

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Metabolic syndrome is associated with adverse health outcomes and is a growing problem worldwide. Although efforts to harmonise the definition of metabolic syndrome have helped to better understand the prevalence and the adverse outcomes associated with the disorder on a global scale, the mechanisms underpinning the metabolic changes that define it are incompletely understood. Accumulating evidence from laboratory and human studies suggests that activation of the sympathetic nervous system has an important role in metabolic syndrome. Indeed, treatment strategies commonly recommended for patients with metabolic syndrome, such as diet and exercise to induce weight loss, are associated with sympathetic inhibition. Pharmacological and device-based approaches to target activation of the sympathetic nervous system directly are available and have provided evidence to support the important part played by sympathetic regulation, particularly for blood pressure and glucose control. Preliminary evidence is encouraging, but whether therapeutically targeting sympathetic overactivity could help to prevent metabolic syndrome and attenuate its adverse outcomes remains to be determined.

AB - Metabolic syndrome is associated with adverse health outcomes and is a growing problem worldwide. Although efforts to harmonise the definition of metabolic syndrome have helped to better understand the prevalence and the adverse outcomes associated with the disorder on a global scale, the mechanisms underpinning the metabolic changes that define it are incompletely understood. Accumulating evidence from laboratory and human studies suggests that activation of the sympathetic nervous system has an important role in metabolic syndrome. Indeed, treatment strategies commonly recommended for patients with metabolic syndrome, such as diet and exercise to induce weight loss, are associated with sympathetic inhibition. Pharmacological and device-based approaches to target activation of the sympathetic nervous system directly are available and have provided evidence to support the important part played by sympathetic regulation, particularly for blood pressure and glucose control. Preliminary evidence is encouraging, but whether therapeutically targeting sympathetic overactivity could help to prevent metabolic syndrome and attenuate its adverse outcomes remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=84921434438&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(14)70033-6

DO - 10.1016/S2213-8587(14)70033-6

M3 - Comment/debate

VL - 3

SP - 148

EP - 157

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

SN - 2213-8587

IS - 2

ER -